Conference
Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin®) induces high response rates and durable remissions in patients with relapsed or refractory B-cell non hodgkin's lymphoma (NHL)
Authors
Murray JL; Witzig TE; Molina A; Gordon L; Emmanouilides C; Vo K; Flinn IW; Czuczman M; Saville W; Wiseman G
Volume
26
Pagination
pp. S48-S49
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
October 31, 2003
Name of conference
18th Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer
Conference place
MARYLAND, BETHESDA
Conference start date
October 31, 2003
Conference end date
November 2, 2003
Conference proceedings
JOURNAL OF IMMUNOTHERAPY
Issue
6
ISSN
1053-8550